Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumours

Titre officiel

A Phase 1 First-in Human, Multi-Centre, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumours

Sommaire:

The study will determine the recommended Phase 2 dose (RP2D) of ABBV-151 administered as monotherapy and in combination with ABBV-181 as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-151 alone and in combination with ABBV-181. The study will consist of 2 phases: dose escalation and dose expansion.

Description de l'essai

Primary Outcome:

  • Dose Escalation: Recommended Phase 2 Dose (RP2D) ABBV-151 Monotherapy
  • Dose Escalation: RP2D ABBV-151 + ABBV-181 Combination Therapy
  • Dose Expansion: Objective Response Rate (ORR)
Secondary Outcome:
  • Dose Expansion: Duration of Response (DOR)
  • Dose Expansion: Progression-free Survival (PFS)
  • Maximum Observed Serum Concentration (Cmax)
  • Time to Maximum Observed Serum Concentration (Tmax)
  • Area Under the Plasma Concentration-time Curve over time from 0 to last measurable concentration (AUCτ)
  • Terminal-phase Elimination Rate Constant (β)
  • Terminal Phase Elimination Half-life (t1/2)

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer